Everything below concerns GHRH receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-06. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
| Property | Value | Notes |
|---|---|---|
| Appearance as powder | White to off-white solid | Minor batch-to-batch variation is normal |
| Solubility class | Soluble in water and aqueous buffers | Dissolution can be slowed by aggregates |
| Typical storage temperature | Minus 20 degrees Celsius or below | Protected from light and moisture |
| Storage after reconstitution | 2 to 8 degrees Celsius, short term | Longer holding requires freezing |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity and identity confirmation |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
=== Diabetes === RAGE plays a pivotal role in the pathogenesis of diabetes. RAGE, a multi-ligand receptor from the immunoglobulin superfamily, primarily binds to Advanced glycation end-products (AGEs) formed through the non-enzymatic glycation of proteins and lipids. In diabetes, hyperglycemia accelerates AGE formation, fostering a pro-inflammatory and pro-oxidative environment that worsens vascular damage and immune cell dysfunction. In both type 1 and type 2 diabetes, RAGE significantly contributes to microvascular and macrovascular complications. It is highly expressed in diabetic blood vessels, cardiomyocytes, podocytes, and immune cells, where it co-localizes with ligands such as AGEs, S100 proteins, and high-mobility group box 1 (HMGB1). This co-localization leads to chronic cellular stress and inflammation, which differs from the transient inflammatory responses associated with acute infections. RAGE activation contributes to complications such as diabetic nephropathy and retinopathy. Studies in diabetic mouse models suggest that blocking RAGE with soluble receptor forms (sRAGE) can mitigate these conditions by reducing mesangial sclerosis, basement membrane thickening, and endothelial damage. Additionally, RAGE's interaction with AGEs and S100 proteins accelerates atherosclerosis in diabetes, marked by increased lesion complexity, macrophage accumulation, and vascular inflammation.
Non-arteritic anterior ischemic optic neuropathy (NAION) is a medical condition characterized by loss of vision caused by damage to the optic nerve as a result of ischemia, or insufficient blood supply. The key symptom of NAION is optic disc swelling, which typically resolves within 2 months, but often leads to optic atrophy. The likelihood of vision improvement after developing this condition is low. NAION is characterized by localized disruptions in blood flow to the optic nerve, often linked with broader systemic vascular conditions. Key risk factors include coronary artery disease, cerebrovascular disease, sleep apnea, diabetes, and hypertension. Currently, there is no universally accepted, scientifically proven treatment for NAION. However, there is a general consensus on the importance of managing underlying risk factors to prevent further complications. This includes controlling blood pressure, managing diabetes, and treating sleep apnea.
== Immunological adjuvants == An adjuvant (from Latin adiuvare – to help) is any substance, distinct from antigen, which enhances immune response by various mechanisms: recruiting of professional antigen-presenting cells (APCs) to the site of antigen exposure; increasing the delivery of antigens by delayed/slow release (depot generation); immunomodulation by cytokine production (selection of Th1 or Th2 response); inducing T-cell response (prolonged exposure of peptide-MHC complexes [signal 1] and stimulation of expression of T-cell-activating co-stimulators [signal 2] on the APCs' surface) and targeting (e. g. carbohydrate adjuvants which target lectin receptors on APCs). Adjuvants have been used as additives to improve vaccine efficiency since the 1920s. Generally, administration of adjuvants is used both in experimental immunology and in clinical settings to ensure a high quality/quantity memory-enhanced antibody response, where antigens must be prepared and delivered in a fashion that maximizes production of a specific immune response. Among commonly used adjuvants are complete and incomplete Freund's adjuvant and solutions of aluminum hydroxide or aluminum phosphate.
1st Special Air Service 2nd Special Air Service 3rd Special Air Service – 3e Régiment de Chasseurs Parachutistes 4th Special Air Service – 2e Régiment de Chasseurs Parachutistes 5th Special Air Service – lineage continued by Belgian Special Forces Group F Squadron – responsible for signals and communications It was tasked with parachute operations behind the German lines in France and carried out operations supporting the Allied advance through France (Operations Houndsworth, Bulbasket, Loyton, Kipling and Wallace-Hardy), Belgium, the Netherlands (Operation Pegasus), and eventually into Germany (Operation Archway and Operation Howard). As a result of Hitler's issuing of the Commando Order on 18 October 1942, the members of the unit faced the additional danger that they would be summarily executed if captured by the Germans. In July 1944, following Operation Bulbasket, 34 captured SAS commandos were indeed summarily executed by the Germans; in October 1944, in the aftermath of Operation Loyton, another 31 captured SAS commandos were summarily executed by the Germans. The last original member of the Special Air Service and the last survivor of the Long Range Desert Group, Mike Sadler, died on 4 January 2024, at the age of 103.
Glutathione synthetase deficiency (GSD) is a rare autosomal recessive metabolic disorder that prevents the production of glutathione. Glutathione helps prevent damage to cells by neutralizing harmful molecules generated during energy production. Glutathione also plays a role in processing medications and cancer-causing compounds (carcinogens), and building DNA, proteins, and other important cellular components.
Sources: en.wikipedia.org
==== Finasteride for androgenetic alopecia (hair loss in men) ==== The most common adverse effects of finasteride taken for hair loss are a decrease in sex drive, erectile dysfunction, and a decrease in the amount of semen. In addition, finasteride has been reported in case reports to cause sexual problems that persist after stopping the medication. A 2012 update to the FDA label noted reports of decreased sex drive, problems with ejaculation and difficulty achieving an erection which continued after stopping the medication. The update also referenced reports of testicular pain and "male infertility and/or poor quality of semen." In 2025, the European Medicines Agency confirmed that suicidal thoughts can occur as a side effect of the hair-loss treatment finasteride and similar dutasteride. The majority of these reports involved patients taking the 1 mg dosage, typically prescribed for androgenetic alopecia, a hormone-related form of hair loss. However, the agency noted that the precise frequency of this adverse effect could not be determined from the data available. In October 2024, the EMA had initiated a review of both finasteride and dutasteride due to concerns over potential links to suicidal ideation. While finasteride—marketed by Organon as Propecia—already includes warnings about possible psychiatric effects, the EMA stated that the evidence did not support a similar link for dutasteride, sold by GSK under the brand name Avodart.
== Sponsorship and philanthropy == In 1972, Church's Chicken sponsored The San Antonio Church's Fried Chicken Inc. First International Chess Tournament, with a first prize of $4,000, resulting in the strongest chess tournament in the United States in 50 years. From 1979 to 1986, Church's Chicken sponsored the ChessCafe Grand Prix tournaments, under the auspices of the United States Chess Federation. Church's Partners Foundation, Inc. is a 501(c)(3) charity that supports the employees of franchisees of Church's Chicken, their families and their communities. The foundation awards $1,000 scholarships to American high school students through their Church's Scholars Program and awarded over $227,000 worth of scholarships in the 2018–2019 academic year. Church's Chicken has partnered with No Kid Hungry since 2016.
The German oculist Burchard Mauchart provided an early description in a 1748 doctoral dissertation of a case of keratoconus, which he called staphyloma diaphanum. However, it was not until 1854 that British physician John Nottingham (1801–1856) clearly described keratoconus and distinguished it from other ectasias of the cornea. Nottingham reported the cases of "conical cornea" that had come to his attention, and described several classic features of the disease, including polyopia, weakness of the cornea, and difficulty matching corrective lenses to the patient's vision. In 1859, British surgeon William Bowman used an ophthalmoscope (recently invented by Hermann von Helmholtz) to diagnose keratoconus, and described how to angle the instrument's mirror so as to best see the conical shape of the cornea. Bowman also attempted to restore vision by pulling on the iris with a fine hook inserted through the cornea and stretching the pupil into a vertical slit, like that of a cat. He reported that he had had a measure of success with the technique, restoring vision to an 18-year-old woman who had previously been unable to count fingers at a distance of 8 inches (20 cm). By 1869, when the pioneering Swiss ophthalmologist Johann Horner wrote a thesis entitled On the treatment of keratoconus, the disorder had acquired its current name.
== External links == Clinical trial number NCT02964104 for "A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin 287 Once Weekly in Subjects With Type 2 Diabetes" at ClinicalTrials.gov Clinical trial number NCT04460885 for "A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 1)" at ClinicalTrials.gov Clinical trial number NCT04795531 for "A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3) (ONWARDS 3)" at ClinicalTrials.gov Clinical trial number NCT04770532 for "A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin (ONWARDS 2)" at ClinicalTrials.gov Clinical trial number NCT04880850 for "A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)" at ClinicalTrials.gov
Sources: en.wikipedia.org
Delayed puberty (and dysmenorrhoea or amenorrhoea in women) in young people Severe kidney damage: high blood sugar can overwork the kidneys, eventually leading to kidney failure and the need for a kidney transplant Severe neuropathy (nerve damage to hands and feet) Extreme fatigue Edema (during blood sugars controlled phases) Heart problems Retinal damage and subsequent vision problems High cholesterol (hypercholesterolaemia) Osteoporosis Death
== External links == Clinical trial number NCT02781727 for "A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)" at ClinicalTrials.gov
==== Other treatments ==== Isotretinoin, a sebosuppressive agent, may be used to reduce sebaceous gland activity as a last resort in refractory disease. Isotretinoin has potentially serious side effects, and few patients with seborrhoeic dermatitis are appropriate candidates for therapy. Topical 0.75% and 1% Metronidazole Topical 4% nicotinamide Topical sulfacetamide Tea tree oil Cannabidiol shampoo Propanediol caprate Frequent washing to avoid the build-up of scale, especially on the scalp, while avoiding overly drying the skin Avoiding damaging skin with harsh grooming or chemical irritants Bicalutamide, an antiandrogen, has been observed in one patient to have potentially been the cause of seborrheic dermatitis relief. However, even if it were demonstrated that bicalutamide or any other antiandrogen is a treatment, it is not recommended due to side effects and price.
Sources: en.wikipedia.org
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.
Hydrolysis, oxidation of susceptible residues, and aggregation all contribute, and their rates depend on pH, temperature, and concentration. Dissolved oxygen and trace metal ions accelerate oxidation. Keeping solutions cold, dilute, and free of unnecessary handling reduces these pathways.
Not always, because the value depends on the detection wavelength, the gradient, and how peak areas are integrated. A figure of ninety-eight percent from one laboratory may not mean the same as the same number from another. Comparing full chromatograms and mass spectra is more informative than comparing a single number.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.